Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Candel Therapeutics Inc
(NQ:
CADL
)
5.330
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Candel Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
November 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
October 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
October 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Looking Into Candel Therapeutics's Recent Short Interest
May 22, 2024
Via
Benzinga
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Candel Therapeutics
Via
GlobeNewswire
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
August 13, 2024
Candel Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
July 18, 2024
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via
Benzinga
How Is The Market Feeling About Candel Therapeutics?
April 19, 2024
Via
Benzinga
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 18, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
June 14, 2024
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Via
News Direct
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
Why BioRestorative Therapies Stock Is Moving Higher Thursday
June 13, 2024
BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic...
Via
Benzinga
Candel Therapeutics to Join Russell 3000® Index
June 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics’ (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
June 07, 2024
--News Direct--
Via
News Direct
12 Health Care Stocks Moving In Monday's After-Market Session
June 03, 2024
Via
Benzinga
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
June 03, 2024
By Jeremy Golden, Benzinga
Via
TheNewswire.com
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
June 03, 2024
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
Via
News Direct
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
May 30, 2024
From
Candel Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 27, 2024
Via
Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
May 24, 2024
Via
Benzinga
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
May 23, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
May 22, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
May 20, 2024
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC
From
Candel Therapeutics
Via
GlobeNewswire
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
May 15, 2024
Via
Benzinga
CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
May 14, 2024
Candel Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
April 25, 2024
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.